Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients

Hikmat Abdel-Razeq,1,2 Salwa S Saadeh,1 Mahmoud Abu-Nasser,1 Hazem Abdulelah,1 Lina Marie,1 Murad Salam,1 Basel Al-Haj Ali,1 Mohammad Ibrahim,1 Dalia Rimawi3 1Department of Internal Medicine, Section of Hematology and Medical Oncology, King Hussein Cancer Center, Amman, Jordan; 2School of Medicine,...

Full description

Bibliographic Details
Main Authors: Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Al-Haj Ali B, Ibrahim M, Rimawi D
Format: Article
Language:English
Published: Dove Medical Press 2018-04-01
Series:OncoTargets and Therapy
Subjects:
Breast cancer
HER2
neoadjuvant
trastuzumab
NSABP-B27
Online Access:https://www.dovepress.com/four-cycles-of-adriamycin-and-cyclophosphamide-followed-by-four-cycles-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/four-cycles-of-adriamycin-and-cyclophosphamide-followed-by-four-cycles-peer-reviewed-article-OTT

Similar Items